Navigation Links
Booster dose not required for Hepatitis B Vaccination

Alessandro Remo Zanetti and his colleagues from Institute of Virology, Italy has found that Initial vaccination with Hepatitis B produces the required concentrations of circulating antibodies in the blood of the patients for long periods//. The researchers have found that the circulating antibodies against Hepatitis B vaccination are present in the blood for at least 10 years after vaccination. Researchers have concluded that there is no need of booster doses of Hepatitis B in these patients as enough amount of antibodies are present which can give protection in case of Hepatitis B infection. The results of the work have been published in the journal The Lancet.

Viral hepatitis B is a leading cause of acute and chronic liver disease worldwide. The World Health Organization (WHO) estimates that, globally, about 2 billion people have been infected with hepatitis B virus (HBV). More than 350 million people are chronically infected. WHO recommends that all countries should have universal infant or adolescent hepatitis B vaccination integrated into their national immunization programs.

The researchers conducted their trial in 1212 children’s and 446 Italian Air Force Recruits by vaccinating with Hepatitis B vaccination. They found that 64% of children and 89% of the recruits retained protective concentrations of antibodies. The study shows that infant and adolescent immune systems can recall responding to hepatitis B more than 10 years after immunization.

Experts View:

Professor Zanetti concludes: “In light of our findings, the use of routine booster doses of hepatitis B vaccine does not seem necessary to maintain long-term protection in immuno-competent individuals vaccinated as infants and teenagers."

Ding-Shinn Chen, National Taiwan University, Taiwan said, “Unless accumulating data show a significant increase of HBV infection in adolescents or adults who were vaccinated as children, a policy of booster vaccination in a population should not be recommended. We believe that this applies both to hyper-endemic and low endemic areas of the world.”

Source: News wise, The Lancet

Related medicine news :

1. Need for Hepatitis Booster Questioned
2. Booster Dose Of Radiotherapy Beneficial In Early Breast Cancer
3. Booster Dose for Chickenpox Vaccine Recommended
4. Care for footwear not required diabetic patients
5. Advanced STD programs required
6. New Stem Cells lines will be required
7. Multi targeted approach required for suicide prevention in adolescents
8. More Funds required for Asian Countries to fight Bird Flu
9. Clergy blasts councilmans required-condom plan
10. Salmeterol - to be used in combination & only when required
11. Vitamin B for Hepatitis
Post Your Comments:

(Date:12/1/2015)... ... , ... Integrated Rental Services (“Integrated Rental”), a growing medical ... , With support from JII, Integrated Rental is poised for expansion while improving ... research labs and medical facilities across the United States. , General Manager Robert ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Califia ... today announced that its iconic bottle has won top honors in Beverage World Magazine’s ... The Company also announced that it has been selected as a 2015 U.S.A. Taste ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... we have seen vast improvements in scientific research and discoveries, leading us to ... increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of ... is the focus of numerous abstracts accepted for presentation here, at the 101st ... Nine abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
(Date:12/1/2015)... 1, 2015 CytRx Corporation (NASDAQ: CYTR ... oncology, today announced that it has reached its enrollment ... Phase 3 clinical trial of aldoxorubicin in patients with ... to be completed in Q1 2016. The Phase 3 trial ... Special Protocol Assessment from the FDA at 79 sites ...
Breaking Medicine Technology: